Topics

Novartis plans FDA approval as it hits endpoint for Consentyx in axial spondyloarthritis

03:56 EDT 3 Oct 2019 | Pharmafile

Novartis has announced positive data from its PREVENT trial, which evaluated the safety and efficacy of Cosentyx (secukinumab) for patients with non-radiographic axial spondyloarthritis, ultimately showing a clinically meaningful reduction in disease activity versus placebo.

The ongoing Phase 3 trial met it primary endpoint at Week 52 and demonstrated a sustained response and a safety profile that was consistent with previous clinical trials.

read more

Original Article: Novartis plans FDA approval as it hits endpoint for Consentyx in axial spondyloarthritis

NEXT ARTICLE

More From BioPortfolio on "Novartis plans FDA approval as it hits endpoint for Consentyx in axial spondyloarthritis"

Quick Search

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Clinical Approvals
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...